First Time Loading...
M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 5.65 USD 0.89% Market Closed
Updated: May 5, 2024
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of GLUE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLUE Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
93.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.5
Industry
26.8
Forward
-2.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
23.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-4.5
Industry
21.4
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
45
vs Industry
53
Median 3Y
1.6
Median 5Y
1.6
Industry
2.6
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
16.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
26
Median 3Y
-1.1
Median 5Y
-1.1
Industry
4.5
Forward
-0.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
25
Median 3Y
-1.1
Median 5Y
-1.1
Industry
4.4
Forward
-0.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
26
Median 3Y
-1.5
Median 5Y
-1.5
Industry
5.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
23
Median 3Y
-1.3
Median 5Y
-1.3
Industry
3.4
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
81
vs Industry
63
Median 3Y
2
Median 5Y
2
Industry
5
More Details

Multiples Across Competitors

GLUE Competitors Multiples
Monte Rosa Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
283.3m USD 0 -2.1 -0.4 -0.4
US
Abbvie Inc
NYSE:ABBV
289.2B USD 5.3 60 13 19.9
US
Amgen Inc
NASDAQ:AMGN
166.7B USD 5.9 24.8 17.9 26.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD 8 26.5 17.8 19.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD 10.5 28.6 22.8 23.9
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.6 21.6 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD 2.9 166.8 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
47.8B USD 7 -10.1 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.7B USD 3.3 27.1 13.9 17.4
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6
EV/EBITDA Multiple
EBITDA Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average EV/EBITDA: 19.8
Negative Multiple: -0.4 		N/A
US
Abbvie Inc
NYSE:ABBV
13
26%
US
Amgen Inc
NASDAQ:AMGN
17.9
62%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
50%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
59%
AU
CSL Ltd
ASX:CSL
21.6
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -11 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
13.9
67%
KR
Celltrion Inc
KRX:068270
44.7
109%

See Also

Summary
GLUE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLUE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLUE stock valuation using valuation multiples.
Wall Street Estimates
GLUE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLUE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.